GT200500229A - Compuestos orgánicos - Google Patents

Compuestos orgánicos

Info

Publication number
GT200500229A
GT200500229A GT200500229A GT200500229A GT200500229A GT 200500229 A GT200500229 A GT 200500229A GT 200500229 A GT200500229 A GT 200500229A GT 200500229 A GT200500229 A GT 200500229A GT 200500229 A GT200500229 A GT 200500229A
Authority
GT
Guatemala
Prior art keywords
organic compounds
cancer
diseases
compounds
ovarians
Prior art date
Application number
GT200500229A
Other languages
English (en)
Inventor
Eiji Kawahara
Takahiro Miyake
Johannes Roesel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT200500229A publication Critical patent/GT200500229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS DERIVADOS DE PIRIMIDINA DE FÓRMULA I, A SU PROCESO DE PRODUCCIÓN, A SU USO EN COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN. ESTOS COMPUESTOS SON USADOS EN EL TRATAMIENTO DE CÁNCER Y DE OTRAS ENFERMEDADES NEOPLÁSICAS: TUMOR DE MAMA, CÁNCER DE COLON, PRÓSTATA, OVARIOS Y PULMON; ENFERMEDADES DEL SISTEMA INMUNOLÓGICO, SNC, FALLAS AL CORAZÓN, HIPERTESIÓN, ETC.
GT200500229A 2004-08-27 2005-08-26 Compuestos orgánicos GT200500229A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0419160.7A GB0419160D0 (en) 2004-08-27 2004-08-27 Organic compounds

Publications (1)

Publication Number Publication Date
GT200500229A true GT200500229A (es) 2006-03-29

Family

ID=33104745

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500229A GT200500229A (es) 2004-08-27 2005-08-26 Compuestos orgánicos

Country Status (24)

Country Link
US (1) US7910585B2 (es)
EP (1) EP1784399B1 (es)
JP (1) JP4674236B2 (es)
KR (1) KR100894349B1 (es)
CN (1) CN101006079A (es)
AR (1) AR050536A1 (es)
AT (1) ATE512960T1 (es)
AU (1) AU2005276585B2 (es)
BR (1) BRPI0514731A (es)
CA (1) CA2575720C (es)
EC (1) ECSP077259A (es)
ES (1) ES2366038T3 (es)
GB (1) GB0419160D0 (es)
GT (1) GT200500229A (es)
IL (1) IL181386A0 (es)
MA (1) MA28813B1 (es)
NO (1) NO20071504L (es)
PE (1) PE20060504A1 (es)
PL (1) PL1784399T3 (es)
PT (1) PT1784399E (es)
RU (1) RU2395507C2 (es)
TN (1) TNSN07074A1 (es)
TW (1) TW200621728A (es)
WO (1) WO2006021457A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
ES2637592T3 (es) 2006-04-14 2017-10-13 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
SI2091918T1 (sl) 2006-12-08 2015-01-30 Irm Llc Spojine in sestavki kot inhibitorji protein-kinaze
AU2007334519A1 (en) * 2006-12-14 2008-06-26 Merck Sharp & Dohme Corp. Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
CA2726508C (en) 2008-06-17 2016-06-07 Astrazeneca Ab Pyridine compounds
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
ES2659725T3 (es) * 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CN101935317B (zh) * 2009-07-01 2013-08-28 上海药明康德新药开发有限公司 2-甲基-7-(取代嘧啶-4-氨基)-4-(取代哌啶-1-基)异吲哚啉-1-酮及中间体的合成方法
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
EP2975403B1 (en) 2013-02-13 2018-05-02 Hirotomo Shibaguchi Rapid allergy testing method
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
BR112022004451A2 (pt) * 2019-09-13 2022-06-21 Nimbus Saturn Inc Antagonistas de hpk1 e usos dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6776480B2 (en) 2001-07-18 2004-08-17 Sola International Holdings, Ltd. Spectacle frames for shaped lenses defined by monoformal carrier surfaces
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) * 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2005276585B2 (en) 2009-07-30
GB0419160D0 (en) 2004-09-29
JP4674236B2 (ja) 2011-04-20
NO20071504L (no) 2007-05-25
RU2007110946A (ru) 2008-10-10
CA2575720C (en) 2012-10-02
BRPI0514731A (pt) 2008-06-24
TW200621728A (en) 2006-07-01
MA28813B1 (fr) 2007-08-01
AU2005276585A1 (en) 2006-03-02
IL181386A0 (en) 2007-07-04
KR20070038567A (ko) 2007-04-10
AR050536A1 (es) 2006-11-01
ECSP077259A (es) 2007-03-29
KR100894349B1 (ko) 2009-04-22
JP2008510765A (ja) 2008-04-10
US7910585B2 (en) 2011-03-22
RU2395507C2 (ru) 2010-07-27
PE20060504A1 (es) 2006-07-18
ES2366038T3 (es) 2011-10-14
CA2575720A1 (en) 2006-03-02
WO2006021457A2 (en) 2006-03-02
WO2006021457A3 (en) 2006-07-13
CN101006079A (zh) 2007-07-25
TNSN07074A1 (en) 2008-06-02
EP1784399A2 (en) 2007-05-16
PT1784399E (pt) 2011-08-26
EP1784399B1 (en) 2011-06-15
PL1784399T3 (pl) 2011-11-30
US20080293708A1 (en) 2008-11-27
ATE512960T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
GT200500229A (es) Compuestos orgánicos
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
ECSP17013466A (es) Inhibidores de desmetilasa-1 específica a lisina
CL2008002982A1 (es) Compuestos derivados de 4,5-difenil-imidazol sustituidos por heterociclos, inhibidores mdm2; composicion farmaceutica que los comprende; proceso de preparacion de los compuestos; y uso en el tratamiento del cancer de mama, colon, pulmon o prostata.
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
CL2008000785A1 (es) Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer.
HN2011000193A (es) Derivados de piridazina como inhibidores de smo
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
MY188934A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MY157661A (en) Bendamustine pharmaceutical compositions
NZ604973A (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
MY156814A (en) Organic compounds and their uses
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CR10056A (es) [(1h-indol-5-il)-heteroariloxi]-(1-aza-biciclo[3.3.1]nonanos como ligandos colinérgicos del n-achr para el tratamiento de trastornos piscóticos y neurodegenerativos
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
AR067769A1 (es) Derivado de ditiazol para el tratamiento del cancer
BR112012029647A2 (pt) novos derivados de pirimidinas
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
MD4643C1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
ECSP17023551A (es) Inhibidores de histona desmetilasa